ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.98
0.00%
US Tech 100
20,877.20
1.72%
S&P 500
5,996.66
1.00%
US Dollar vs CAD
1.44565
-0.13%
Bitcoin
106,905.85
3.67%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. EyePoint Pharmaceuticals Inc (EYPT)

  7. EyePoint Pharmaceuticals Inc (EYPT) News

EYPT

EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EYPT
DateTimeSourceHeadlineSymbolCompany
01/16/20256:00AMGlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/13/20256:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/13/20256:00AMGlobeNewswire Inc.EyePoint Provides Company Update and Anticipated Development Milestones for 2025NASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/08/20253:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/08/20253:11PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/08/20256:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/08/20256:00AMGlobeNewswire Inc.EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of DirectorsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/07/20253:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/07/20253:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/07/20253:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/07/20253:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/07/20253:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
12/17/20246:00AMGlobeNewswire Inc.EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
12/16/20246:00AMGlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
12/04/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
12/04/20246:00AMGlobeNewswire Inc.EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
11/18/20246:00AMGlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
11/14/20242:10PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
11/07/20243:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
11/07/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
11/07/20246:00AMGlobeNewswire Inc.EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
11/04/20246:00AMGlobeNewswire Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/31/20243:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/31/20243:00PMGlobeNewswire Inc.EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/30/20243:20PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/29/20248:47PMGlobeNewswire Inc.EyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingNASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/28/20244:17PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/28/20244:14PMGlobeNewswire Inc.EyePoint Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/28/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/28/20246:00AMGlobeNewswire Inc.EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular EdemaNASDAQ:EYPTEyePoint Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EYPT

Your Recent History

NASDAQ
DMAT
Global X Disruptive Mate...
BIT
W301R4
UBS
LSE
OPG
Opg Power Ventures
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads